Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2015, Article ID 962574, 6 pages
http://dx.doi.org/10.1155/2015/962574
Research Article

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

1University of Liverpool, Liverpool, UK
2Folateng Ward, Sebokeng Hospital, Gauteng, South Africa
3Janssen Research and Development, LLC, Titusville, NJ, USA
4Janssen Global Public Health, Tilburg, Netherlands
5Janssen Global Public Health, High Wycombe, UK

Received 26 March 2015; Accepted 1 July 2015

Academic Editor: Andrea Mangano

Copyright © 2015 Anna Maria Geretti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UNAIDS, “The 2014 GAP report,” December 2014, http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.
  2. The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group, “Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice,” AIDS, vol. 19, no. 5, pp. 487–494, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Von Wyl, S. Yerly, J. Böni et al., “Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types,” Archives of Internal Medicine, vol. 167, no. 16, pp. 1782–1790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. World Health Organization, Consolidated Guidelines on the Use of Antiretroviral Drugs for the Treatment and Prevention of HIV Infection, World Health Organization, Geneva, Switzerland, 2013, http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
  5. MSF Drug Access Team, Untangling the Web of Antiretroviral Price Reductions, MSF Drug Access, Geneva, Switzerland, 17th edition, 2014, http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-17th-edition-%E2%80%93-july-2014.
  6. R. Ortiz, E. DeJesus, H. Khanlou et al., “Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48,” AIDS, vol. 22, no. 12, pp. 1389–1397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Orkin, E. DeJesus, A. Stoehr et al., “ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive HIV-1-infected adults,” Journal of the International AIDS Society, vol. 13, supplement 4, p. P3, 2010. View at Google Scholar
  8. J. V. Madruga, D. Berger, M. McMurchie et al., “Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled Phase III trial,” The Lancet, vol. 370, no. 9581, pp. 49–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Koulia-Shiro, L. Ciaffi, V. le Moing et al., “Randomized comparison of three second-line ART regimens in Africa: the 2LADY/ANRS/EDCTP study,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '14), Abstract 541LB, Boston, Mass, USA, March 2014.
  10. R. Landowitz, H. Ribaudo, I. Ofotokun et al., “Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTV/tenofovir: ACTG 5257,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI '14), Abstract 85, Boston, Mass, USA, March 2014.
  11. M. Johnson, B. Grinsztejn, C. Rodriguez et al., “Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures,” AIDS, vol. 19, no. 7, pp. 685–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Cahn, J. Fourie, B. Grinsztejn et al., “Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients,” AIDS, vol. 25, no. 7, pp. 929–939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Sension, P. Cahn, P. Domingo et al., “Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial,” HIV Medicine, vol. 14, no. 7, pp. 437–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. SECOND-LINE Study Group, “Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study,” The Lancet, vol. 381, no. 9883, pp. 2091–2099, 2013. View at Publisher · View at Google Scholar
  15. N. I. Paton, C. Kityo, A. Hoppe et al., “Assessment of second-line antiretroviral regimens for HIV therapy in Africa,” The New England Journal of Medicine, vol. 371, no. 3, pp. 234–247, 2014. View at Publisher · View at Google Scholar · View at Scopus